Hims & Hers Health’s stock jumped more than 30% Monday morning after the health and wellness platform said it would offer compounded versions of popular GLP-1 drugs.
Hims & Hers Health says it will offer compounded GLP-1 drugs, despite FDA warnings
Read Next
- NVIDIA’s EMBark Revolutionizes Large-Scale Recommendation System Training
- RBI Guv Shaktikanta Das, ET BFSI
- NZD/USD Under Pressure Amidst USD Strength :: InvestMacro
- Bitcoin (BTC) Surges to New Heights Amidst Robust Capital Inflows
- LIC losses nearly Rs 9000 crore; PSBs witness fall, ET BFSI
- People who become easier to manipulate as they get older typically display these 8 behaviors (without realizing it)
- CFPB expands oversight of Apple Pay, other digital payments services
